[AXGN] AxoGen, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 8.5 Change: -0.05 (-0.58%)
Ext. hours: Change: 0 (0%)

chart AXGN

Refresh chart

Strongest Trends Summary For AXGN

AXGN is in the long-term up 485% in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: AxoGen, Inc. operates as a medical technology company. It focuses on advancing the science and commercialization of peripheral nerve repair solutions. It offers a range of surgical nerve repair solutions, including Avance Nerve Graft, a processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. The company?s products are used by plastic reconstructive surgeons, and orthopedic and plastic surgeons during surgical interventions to repair various nerve injuries. It procures and processes its tissue products in the United States, Canada, Italy, Austria, the United Kingdom, the Netherlands, Israel, and Switzerland. AxoGen, Inc. is headquartered

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 17.49% Sales Growth - Q/Q3.27% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-60.58% ROE2506.62% ROI
Current Ratio7.57 Quick Ratio6.6 Long Term Debt/Equity1.12 Debt Ratio-5.05
Gross Margin80.01% Operating Margin-50.21% Net Profit Margin-91.49% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities13.59 M Cash From Operating Activities-40 K Gross Profit3.97 M
Net Profit-2.51 M Operating Profit-2.54 M Total Assets28.14 M Total Current Assets26.02 M
Total Current Liabilities3.44 M Total Debt25.27 M Total Liabilities28.82 M Total Revenue4.95 M
Technical Data
High 52 week55.9 Low 52 week14.62 Last close14.62 Last change-11.98%
RSI34.8 Average true range1.7 Beta0.31 Volume57.96 K
Simple moving average 20 days-18.76% Simple moving average 50 days-44.83% Simple moving average 200 days-61.88%
Performance Data
Performance Week-5.86% Performance Month-48.88% Performance Quart-57.72% Performance Half-71.33%
Performance Year-47.32% Performance Year-to-date-28.44% Volatility daily8.98% Volatility weekly20.07%
Volatility monthly41.13% Volatility yearly142.48% Relative Volume176.98% Average Volume814.29 K
New High New Low

News

2020-05-20 07:00:10 | Axogen, Inc. to Present at the Jefferies Virtual Healthcare Conference

2020-05-07 12:00:48 | AxoGen Inc AXGN Q1 2020 Earnings Call Transcript

2020-05-07 04:35:30 | Edited Transcript of AXGN earnings conference call or presentation 6-May-20 8:30pm GMT

2020-05-06 16:01:10 | Axogen, Inc. Reports First Quarter 2020 Financial Results

2020-04-29 12:34:04 | Earnings Preview: AxoGen AXGN Q1 Earnings Expected to Decline

2020-04-23 07:00:10 | Axogen, Inc. Reports Preliminary Revenue for the First Quarter 2020, Provides Business Update in Response to COVID-19 Pandemic, and Announces Dismissal of Class Action Lawsuit

2020-04-15 07:00:10 | Axogen, Inc. to Report First Quarter 2020 Financial Results and Host Conference Call on May 6, 2020

2020-04-12 09:21:13 | Is AxoGen, Inc.'s NASDAQ:AXGN CEO Being Overpaid?

2020-03-04 20:54:58 | Edited Transcript of AXGN earnings conference call or presentation 24-Feb-20 9:30pm GMT

2020-03-02 07:00:10 | Axogen, Inc. to Participate at Upcoming Investor Conferences

2020-02-27 07:20:46 | AxoGen, Inc. Just Reported, And Analysts Assigned A US$22.17 Price Target

2020-02-24 16:01:10 | Axogen, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results

2020-02-23 18:38:25 | The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

2020-02-05 07:00:10 | Axogen, Inc. to Present at the Leerink Partners 9th Annual Global Healthcare Conference

2020-02-03 07:00:10 | Axogen, Inc. to Report Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call on February 24, 2020

2020-02-03 05:55:13 | How Many AxoGen, Inc. NASDAQ:AXGN Shares Did Insiders Buy, In The Last Year?

2020-01-13 07:00:10 | Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2019 and Provides 2020 Annual Guidance

2020-01-08 07:00:10 | Axogen Sponsored RANGER® Registry Reaches 2,000 Nerve Repair Enrollment Milestone

2020-01-02 16:01:10 | Axogen to Participate at AAHS ASPN ASRM 2020 Annual Meetings

2020-01-02 07:00:10 | Axogen, Inc. to Participate at JP Morgan 38th Annual Healthcare Conference

2019-12-19 06:47:16 | Can You Imagine How Elated AxoGen's NASDAQ:AXGN Shareholders Feel About Its 335% Share Price Gain?

2019-12-18 07:00:10 | Axogen awarded research grant from the Advanced Regenerative Manufacturing Institute

2019-12-13 11:03:05 | Hedge Funds Cashed Out Of AxoGen, Inc. AXGN Too Early

2019-12-04 07:00:10 | Avance® Nerve Graft Recipient Selected to Ride on Donate Life Rose Parade® Float

2019-11-22 12:19:02 | Edited Transcript of AXGN earnings conference call or presentation 6-Nov-19 9:30pm GMT

2019-11-21 07:00:00 | Axogen, Inc. to Participate at Piper Jaffray 31st Annual Healthcare Conference

2019-11-11 07:00:00 | Axogen, Inc. to Participate at Jefferies London Healthcare Conference

2019-11-09 19:02:32 | Hedge Funds Aren’t Crazy About AxoGen, Inc. AXGN Anymore

2019-11-06 18:35:11 | AxoGen AXGN Reports Q3 Loss, Tops Revenue Estimates

2019-11-06 16:04:37 | Axogen, Inc. Reports 2019 Third Quarter Financial Results

2019-11-04 06:12:57 | Here's Why We're Not Too Worried About AxoGen's NASDAQ:AXGN Cash Burn Situation

2019-10-30 10:34:02 | Earnings Preview: AxoGen AXGN Q3 Earnings Expected to Decline

2019-10-23 07:00:05 | Axogen, Inc. to Report Third Quarter 2019 Financial Results and Host Conference Call on November 6, 2019

2019-10-03 13:40:00 | Scott+Scott Attorneys at Law LLP Investigating Axogen, Inc.'s Directors and Officers for Breach of Fiduciary Duties - AXGN

2019-09-20 10:38:00 | Why AxoGen, Inc.'s NASDAQ:AXGN CEO Pay Matters To You

2019-09-19 07:00:00 | Axogen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference

2019-09-11 20:00:00 | Bragar Eagel & Squire is Investigating Certain Officers and Directors of Mammoth Energy, Acer Therapeutics, Realogy Holdings, and AxoGen and Encourages Investors to Contact the Firm

2019-08-27 07:00:00 | Axogen to Participate in the 74th Annual American Society for Surgery of the Hand Meeting

2019-08-18 17:59:18 | Weekly CEO Buys Highlight

2019-08-14 21:02:29 | Bragar Eagel & Squire is Investigating Certain Officers and Directors of Lannett, Molson Coors, AxoGen, and American Renal Associates and Encourages Investors to Contact the Firm

2019-08-14 13:55:00 | Shareholder Alert: Robbins Arroyo LLP Announces Complaint Filed Against AxoGen, Inc. AXGN

2019-08-12 10:15:02 | Axogen Inc AXGN CEO Karen L. Zaderej Bought $1 million of Shares

2019-08-07 05:04:11 | Edited Transcript of AXGN earnings conference call or presentation 6-Aug-19 8:30pm GMT

2019-08-06 20:24:22 | AxoGen Inc AXGN Q2 2019 Earnings Call Transcript

2019-08-06 18:55:10 | AxoGen AXGN Reports Q2 Loss, Misses Revenue Estimates

2019-08-06 14:11:53 | Does AxoGen NASDAQ:AXGN Have A Healthy Balance Sheet?

2019-07-30 10:38:02 | Earnings Preview: AxoGen AXGN Q2 Earnings Expected to Decline

2019-07-29 07:00:00 | Axogen, Inc. to Participate at Canaccord Genuity 39th Annual Growth Conference

2019-07-26 07:50:00 | AXGN Alert: Johnson Fistel, LLP Announces Investigation of AxoGen, Inc.; Long Term Investors Encouraged to Contact Firm

2019-07-26 07:00:00 | Axogen Announces Publication of the 100th Peer-Reviewed Clinical Paper Featuring its Product Portfolio for Peripheral Nerve Repair